Drug Profile
Strontium malonate
Alternative Names: NB S101; NSB-101Latest Information Update: 23 Jul 2015
Price :
$50
*
At a glance
- Originator Osteologix Inc
- Class Heavy metals; Osteoporosis therapies
- Mechanism of Action Bone resorption factor inhibitors; Osteogenesis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Postmenopausal osteoporosis
Most Recent Events
- 05 Aug 2011 Strontium malonate is available for licensing in USA as of 05 Aug 2011. http://www.osteologix.com
- 03 Aug 2010 Strontium malonate licensed to Servier worldwide, except in the US
- 17 Feb 2009 Osteologix holds meeting with the US FDA on the proposed development of strontium malonate for Osteoporosis